GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » Degree of Operating Leverage

ONCT (Oncternal Therapeutics) Degree of Operating Leverage : 0.00 (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Oncternal Therapeutics does not have enough data to calculate Degree of Operating Leverage.


Oncternal Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Oncternal Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Degree of Operating Leverage Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncternal Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncternal Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Oncternal Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncternal Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Degree of Operating Leverage falls into.


;
;

Oncternal Therapeutics Degree of Operating Leverage Calculation

Oncternal Therapeutics's Degree of Operating Leverage for the quarter that ended in Sep. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -35.959 (Sep. 2024) / -43.993 (Sep. 2023) - 1 )/( 0 (Sep. 2024) / 0 (Sep. 2023) - 1 )
=-0.1826/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Oncternal Therapeutics  (NAS:ONCT) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Oncternal Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Executives
Robert James Wills director, officer: Executive Chairman 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Gunnar F. Kaufmann officer: Chief Scientific Officer C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji officer: Chief Medical Officer 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer director, officer: President, CEO
Richard G Vincent officer: Chief Financial Officer C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan officer: Chief Technology Officer 12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen director 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
Hazel M Aker officer: General Counsel C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Shanghai Pharmaceutical (usa) Inc. 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Shanghai Pharmaceuticals (hk) Investment Ltd 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130